-
Something wrong with this record ?
Haemanthamine alters sodium butyrate-induced histone acetylation, p21WAF1/Cip1 expression, Chk1 and Chk2 activation and leads to increased growth inhibition and death in A2780 ovarian cancer cells
M. Seifrtová, R. Havelek, L. Cahlíková, D. Hulcová, N. Mazánková, M. Řezáčová,
Language English Country Germany
Document type Journal Article
- MeSH
- Acetylation MeSH
- Transcriptional Activation drug effects MeSH
- Amaryllidaceae Alkaloids pharmacology MeSH
- Cell Division drug effects MeSH
- Cell Cycle drug effects MeSH
- Checkpoint Kinase 1 metabolism MeSH
- Checkpoint Kinase 2 metabolism MeSH
- Phenanthridines pharmacology MeSH
- Phosphorylation MeSH
- Histones metabolism MeSH
- Cyclin-Dependent Kinase Inhibitor p21 metabolism MeSH
- Butyric Acid pharmacology MeSH
- Humans MeSH
- Cell Line, Tumor MeSH
- Ovarian Neoplasms pathology MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Haemanthamine (HA) and sodium butyrate (NaB) are promising candidates for chemotherapy as a treatment for cancer. PURPOSE: We aimed to determine the anticancer potential of HA and NaB, alone and in combination, in A2780 ovarian cancer cells and concurrently investigated anticancer potential in contrast to non-cancer human MRC-5 fibroblasts. METHODS: Antiproliferative effects were determined by WST-1 assay and by Trypan blue exclusion staining. Cell cycle distributions were studied by flow cytometry and protein levels were determined by Western blotting. RESULTS: The combination of HA and NaB caused a significant decrease in the proliferation of A2780 cells compared to the stand-alone treatment of cells by HA or NaB. This effect was less pronounced in non-cancer MRC-5 fibroblasts. In the later intervals, the number of A2780 living cells was strongly decreased by treatment using a combination of NaB and HA. This simultaneous application had no considerable effect in MRC-5 fibroblasts. The combination of NaB and HA led to the suppression of cells in the G1 phase and caused an accumulation of cells in the S and G2 phase in comparison to those treated with NaB and HA alone. Treatment of cells with NaB alone led to the activation of proteins regulating the cell cycle. Notably, p21WAF1/Cip1 was upregulated in both A2780 and MRC-5 cells, while checkpoint kinases 1 and 2 were activated via phosphorylation only in A2780 cells. Unexpectedly, NaB in combination with HA suppressed the phosphorylation of Chk2 on threonine 68 and Chk1 on serine 345 in A2780 cells and downregulated p21WAF1/Cip1 in both tested cell lines. The sensitization of cells to HA and NaB treatment seems to be accompanied by increased histone acetylation. NaB-induced acetylation of histone H3 and H4 and histone acetylation increased markedly when a combination of NaB and HA was applied. Whereas the most prominent hyperacetylation after HA and NaB treatment was observed in A2780 cells, the acetylation of histones occurred in both cell lines. CONCLUSION: In summary, we have demonstrated the enhanced activity of HA and NaB against A2780 cancer cells, while eliciting no such effect in non-cancer MRC-5 cells.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18016293
- 003
- CZ-PrNML
- 005
- 20180521091657.0
- 007
- ta
- 008
- 180515s2017 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.phymed.2017.08.019 $2 doi
- 035 __
- $a (PubMed)28991639
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Seifrtová, Martina $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, Hradec Kralove 500 38, Czech Republic. Electronic address: seifrtovam@lfhk.cuni.cz.
- 245 10
- $a Haemanthamine alters sodium butyrate-induced histone acetylation, p21WAF1/Cip1 expression, Chk1 and Chk2 activation and leads to increased growth inhibition and death in A2780 ovarian cancer cells / $c M. Seifrtová, R. Havelek, L. Cahlíková, D. Hulcová, N. Mazánková, M. Řezáčová,
- 520 9_
- $a BACKGROUND: Haemanthamine (HA) and sodium butyrate (NaB) are promising candidates for chemotherapy as a treatment for cancer. PURPOSE: We aimed to determine the anticancer potential of HA and NaB, alone and in combination, in A2780 ovarian cancer cells and concurrently investigated anticancer potential in contrast to non-cancer human MRC-5 fibroblasts. METHODS: Antiproliferative effects were determined by WST-1 assay and by Trypan blue exclusion staining. Cell cycle distributions were studied by flow cytometry and protein levels were determined by Western blotting. RESULTS: The combination of HA and NaB caused a significant decrease in the proliferation of A2780 cells compared to the stand-alone treatment of cells by HA or NaB. This effect was less pronounced in non-cancer MRC-5 fibroblasts. In the later intervals, the number of A2780 living cells was strongly decreased by treatment using a combination of NaB and HA. This simultaneous application had no considerable effect in MRC-5 fibroblasts. The combination of NaB and HA led to the suppression of cells in the G1 phase and caused an accumulation of cells in the S and G2 phase in comparison to those treated with NaB and HA alone. Treatment of cells with NaB alone led to the activation of proteins regulating the cell cycle. Notably, p21WAF1/Cip1 was upregulated in both A2780 and MRC-5 cells, while checkpoint kinases 1 and 2 were activated via phosphorylation only in A2780 cells. Unexpectedly, NaB in combination with HA suppressed the phosphorylation of Chk2 on threonine 68 and Chk1 on serine 345 in A2780 cells and downregulated p21WAF1/Cip1 in both tested cell lines. The sensitization of cells to HA and NaB treatment seems to be accompanied by increased histone acetylation. NaB-induced acetylation of histone H3 and H4 and histone acetylation increased markedly when a combination of NaB and HA was applied. Whereas the most prominent hyperacetylation after HA and NaB treatment was observed in A2780 cells, the acetylation of histones occurred in both cell lines. CONCLUSION: In summary, we have demonstrated the enhanced activity of HA and NaB against A2780 cancer cells, while eliciting no such effect in non-cancer MRC-5 cells.
- 650 _2
- $a acetylace $7 D000107
- 650 _2
- $a alkaloidy amarylkovitých $x farmakologie $7 D047151
- 650 _2
- $a kyselina máselná $x farmakologie $7 D020148
- 650 _2
- $a buněčný cyklus $x účinky léků $7 D002453
- 650 _2
- $a buněčné dělení $x účinky léků $7 D002455
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a checkpoint kinasa 1 $x metabolismus $7 D000071877
- 650 _2
- $a checkpoint kinasa 2 $x metabolismus $7 D064447
- 650 _2
- $a inhibitor p21 cyklin-dependentní kinasy $x metabolismus $7 D050759
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a histony $x metabolismus $7 D006657
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory vaječníků $x patologie $7 D010051
- 650 _2
- $a fenantridiny $x farmakologie $7 D010617
- 650 _2
- $a fosforylace $7 D010766
- 650 _2
- $a aktivace transkripce $x účinky léků $7 D015533
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Havelek, Radim $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, Hradec Kralove 500 38, Czech Republic.
- 700 1_
- $a Cahlíková, Lucie $u ADINACO Research Group, Department of Pharmaceutical Botany and Ecology, Faculty of Pharmacy, Charles University in Prague, Heyrovského 1203, Hradec Králové 500 05, Czech Republic.
- 700 1_
- $a Hulcová, Daniela $u ADINACO Research Group, Department of Pharmaceutical Botany and Ecology, Faculty of Pharmacy, Charles University in Prague, Heyrovského 1203, Hradec Králové 500 05, Czech Republic.
- 700 1_
- $a Mazánková, Naděžda $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, Hradec Kralove 500 38, Czech Republic.
- 700 1_
- $a Řezáčová, Martina $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, Hradec Kralove 500 38, Czech Republic.
- 773 0_
- $w MED00003830 $t Phytomedicine international journal of phytotherapy and phytopharmacology $x 1618-095X $g Roč. 35, č. - (2017), s. 1-10
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28991639 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180521091839 $b ABA008
- 999 __
- $a ok $b bmc $g 1299917 $s 1013133
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 35 $c - $d 1-10 $e 20170819 $i 1618-095X $m Phytomedicine $n Phytomedicine $x MED00003830
- LZP __
- $a Pubmed-20180515